8-K: Quipt Rejects Forager's "Undervalued" $3.10 Per Share Offer

Quipt Home Medical Corp. confirmed its board rejected Forager Capital Management's latest unsolicited, non-binding acquisition proposal of US$3.10 per share, citing undervaluation and self-serving tactics.

Summary

• Quipt Home Medical Corp. received another unsolicited, non-binding proposal from Forager Capital Management, LLC (FCM) on August 25, 2025, to acquire all common shares for US$3.10 per share.
• This August Proposal follows several prior, similarly non-binding offers from FCM, including a publicly disclosed US$3.10 offer on May 19, 2025.
• FCM previously made a non-binding offer in January 2025 to acquire all shares at US$3.90 per share, which was 26% higher than the current offer.
• The Board declined the January Proposal, determining it undervalued the Company and was not in the best interests of shareholders.
• Since the January Proposal, Quipt has acquired a full-service durable medical equipment provider from Ballad Health, adding unaudited revenue of $6.6 million.
• Quipt also entered a joint venture to acquire a 60% ownership interest in Hart Medical Equipment, adding unaudited revenue of $60 million and $7 million of Adjusted EBITDA.
• The Company has also stabilized its revenue.
• The Board expresses concerns about FCM's credibility due to the reduced offer price, failure to disclose the January Proposal in required U.S. securities filings (Schedule 13D), and repeated refusal to engage through Quipt's financial advisor, Truist Securities, Inc.
• The Board believes FCM's offers significantly undervalue the Company and questions FCM's true motives due to its failure to constructively engage and comply with U.S. securities law and a Non-Disclosure and Standstill Agreement.
• The Board is willing to engage with FCM on a friendly basis if FCM agrees to and complies with a confidentiality agreement to determine if a realistic, value-adding bid can be made.
• The Board, advised by Truist and legal counsel, remains committed to safeguarding and enhancing long-term shareholder value.

Sentiment

Score: 6

Explanation: The company's board is actively protecting shareholder value by rejecting an undervalued offer, especially after significant recent growth. However, the ongoing unsolicited bids and the bidder's questionable tactics introduce a degree of uncertainty and potential distraction.

Positives

• The Board is actively protecting shareholder value by rejecting an offer deemed significantly undervalued, especially given recent company growth.
• Quipt has demonstrated significant growth and improved financial performance since January 2025, including two strategic acquisitions:
• Acquisition of a full-service durable medical equipment provider from Ballad Health, adding unaudited revenue of $6.6 million.
• Joint venture to acquire a 60% ownership interest in Hart Medical Equipment, adding unaudited revenue of $60 million and $7 million of Adjusted EBITDA.
• The Company has stabilized its revenue, indicating operational strength.
• The Board is open to constructive engagement with FCM under proper confidentiality terms, signaling a willingness to consider genuinely value-adding proposals.

Negatives

• FCM's repeated unsolicited, non-binding offers create uncertainty and potential distraction for management and the Board.
• The current offer of US$3.10 per share is significantly lower (26% less) than FCM's previous offer of US$3.90 per share in January 2025, despite Quipt's recent growth.
• FCM's alleged non-compliance with U.S. securities laws (failure to report the January Proposal in an amended Schedule 13D) and contractual obligations under a Non-Disclosure and Standstill Agreement raises concerns about its integrity and motives.
• FCM's refusal to engage through proper channels (Quipt's financial advisor, Truist Securities, Inc.) suggests a potentially hostile or self-serving approach.

Risks

• The ongoing unsolicited offers and public tactics by FCM could create market uncertainty regarding Quipt's future strategic direction.
• Potential for distraction of management and the Board from core business operations due to dealing with repetitive, undervalued proposals.
• Risk of FCM continuing disruptive tactics, which could negatively impact shareholder sentiment and share price volatility.
• Potential for misinterpretation by the market regarding the Board's rejection, despite clear communication of undervaluation.

Future Outlook

The Board remains firmly committed to safeguarding and enhancing long-term shareholder value. The Company does not intend to comment further on the engagement of Truist, FCM's offers, or any related matter unless additional disclosure is appropriate or required. Quipt seeks to continue expanding its offerings to manage several chronic disease states and aims to increase annual revenue per patient by offering multiple services.

Management Comments

• "It is therefore unclear how FCM thinks the August Proposal should be taken seriously by the Board or any shareholders of the Company."
• "The fact that FCM has since reduced its offer price, while also failing to disclose the January Proposal in its required U.S. securities filings, raises further concerns about its credibility."
• "FCM continues to bypass proper channels and make self-serving public offers that the Board believes significantly undervalue the Company."
• "This failure to constructively engage with the Company, coupled with its failures to comply with U.S. securities law and its contractual obligations under the Non-Disclosure and Standstill Agreement with the Company, calls into question the true motives of FCM."
• "If FCM agrees to enter into and actually comply with a confidentiality agreement with the Company, the Board would be pleased to engage with FCM on a friendly basis in an effort to determine if FCM could realistically make a bid that would provide real value to its fellow shareholders."
• "Acting with the benefit of advice from Truist and its legal counsel, the Board remains firmly committed to safeguarding and enhancing long-term shareholder value."

Industry Context

Quipt operates in the U.S. home medical equipment market, focusing on end-to-end respiratory care and chronic disease management. The company's strategy involves organic growth by increasing revenue per patient through multiple services and strategic acquisitions/joint ventures to expand its service offerings and market reach, which aligns with broader trends in healthcare towards in-home care and integrated patient management.

Corporate Governance

Legal Proceedings

• FCM allegedly failed to comply with U.S. securities laws by not publicly reporting its January 2025 proposal in an amended Schedule 13D.
• FCM allegedly failed to comply with its contractual obligations under a Non-Disclosure and Standstill Agreement with Quipt.

Stakeholder Impact

• Shareholders: The Board's rejection of an undervalued offer aims to protect and enhance long-term shareholder value. The ongoing unsolicited bids could create short-term volatility but the Board's firm stance provides clarity.
• Management: The process of dealing with unsolicited bids and ensuring compliance with legal and contractual obligations may divert management's focus from core business operations.
• Customers: Continued focus on expanding services and organic growth benefits customers through broader offerings and integrated care.

Next Steps

• The Company does not intend to comment further on the engagement of Truist, FCM's offers, or any related matter unless additional disclosure is appropriate or required.
• The Board is open to engaging with FCM on a friendly basis if FCM agrees to and complies with a confidentiality agreement to explore a realistic, value-adding bid.
• Quipt plans to continue expanding its offerings to manage chronic disease states and increase annual revenue per patient.

Key Dates

Recommendation

While the Board's rejection of an undervalued offer and the company's recent growth are positive, the persistent unsolicited bids from Forager Capital Management introduce uncertainty. The situation could evolve into a more formal takeover battle or a revised, higher offer, or it could simply be a distraction that eventually fades. Investors should hold to monitor developments, particularly any further engagement with FCM or other strategic alternatives the Board might pursue, as well as the company's continued execution of its growth strategy.

Keywords

Home Medical Equipment, Respiratory Care, Durable Medical Equipment, DME, Acquisition, Joint Venture, Shareholder Value, Takeover Bid, Unsolicited Offer, Forager Capital Management, Quipt Home Medical, QIPT, NASDAQ, TSX, Corporate Governance, SEC Filing, 8-K